The province is currently finalizing all the necessary steps to begin vaccination campaigns against influenza and Covid-19 next week. All this comes after a final season in which the Zamorans responded above average.
Elderly and at-risk people flock to health centers. In fact, 85% of those over 75 years old have been vaccinated, a figure that drops by 8 percentage points (77%) in the 60 to 65 age group and reaches almost 70% among those aged 59 or younger. The total number of vaccinations last time reached 58,280, 12% of which were administered to people under the age of 59.
Awareness campaigns targeting influenza and Covid-19 will be run independently, starting on October 3 at seniors’ centres, and continuing from October 10 on the general population for whom vaccination is recommended. Health and social hygiene workers will be able to receive both vaccines at their workplaces through reference occupational health services, while for other groups, vaccination points and appointment methods will be established in each health region. Social, demographic and health conditions, etc.
Looking ahead to the 2023/2024 vaccination campaign, Zamora will receive 66,057 doses, although currently the province’s planned profit is 6,000 doses. In addition to this, there are 700 units of niversivimab, a drug that fights the respiratory syncytial virus known as bronchiolitis. At the regional level, the Ministry of Health has arranged to purchase 805,500 doses of influenza vaccine. Total expenditure was €10,527,058, which included a new intranasal vaccine for children aged 24 to 59 months.
Vaccination requests will be made by requesting an appointment. Sacyl Conecta, self-administered through the Castile and León government website or at health centers.
A novelty in this year’s immunization program is the emergence of a new drug called Nirsevimab, which helps immunize against the respiratory syncytial virus (RSV), known as bronchiolitis. Zamora has 700 doses of the drug. In this way, children born between March 1, 2023 and March 31, 2024 can receive a single dose of the vaccine.
Depending on the child’s date of birth, the vaccine will be administered in a hospital or health center, so children born on or after October 1 will receive the monoclonal antibody at the birth hospital, while children born on or after October 1 will receive it at the birth hospital. The hospital accepts monoclonal antibody vaccination. Doses will be received in the usual health centers or vaccination centers in March and September.
For a group of infants at high risk for severe RSV disease, preterm infants younger than 35 weeks will receive a single dose of the new drug Nirsevimad before they are 12 months old. Patients with congenital heart disease, bronchopulmonary dysplasia, or severe immunosuppression will receive this drug before each RSV season, before age 24 months, and at the time of immunization.
Vaccination of susceptible groups
Flu and Covid-19 vaccinations are recommended for:
- Persons 60 years of age or older.
- Persons 5 years of age or older in disability centers and nursing homes, as well as other long-term residents and residents of closed institutions.
- People under 60 years of age with the following risk conditions: diabetes and Cushing’s syndrome, morbid obesity, chronic cardiovascular, neurological or respiratory disease (including bronchopulmonary dysplasia), cystic fibrosis and asthma, chronic kidney disease and kidney disease Syndrome, hemoglobinopathies and anemia or hemophilia, other coagulation disorders and chronic bleeding disorders, as well as patients with blood products and multiple transfusions, asplenia or severe splenic dysfunction, chronic liver disease (including chronic alcoholism), severe neuromuscular Disease, immunosuppressive (including primary immunodeficiency and HIV-induced immunodeficiency) infections or drugs, and transplant recipients and complement deficiencies, cancer and hematological malignancies, cerebrospinal fluid fistulas and cochlear implantation or waiting, celiac disease, Chronic inflammatory diseases, conditions and diseases that lead to cognitive impairment – Down syndrome, dementia and others.
- Pregnant women in any trimester of pregnancy and women in the postpartum period (up to 6 months postpartum) who were not vaccinated during pregnancy.
- People who live with highly immunosuppressed people.
- Staff in public and private health and social care centres.
- and those working in essential public services such as national security forces, firefighters or civil defence.
In addition to the above, it is recommended that the following groups of people receive influenza vaccination:
- Population of children aged 6 to 59 months. This is a novelty in the immunization calendar of Castilla and León. Children 6 to 23 months will receive the vaccine intramuscularly, and children 24 to 59 months will receive the vaccine intranasally.
- Education center staff at any educational level.
- People between the ages of 5 and 59 are at higher risk for complications from the flu. This group includes smokers.
- Students undertake internships at the Center for Health and Social Care.
- People who work on a farm, poultry farm, pig farm or mink farm or come into contact with wild animals.
Specifically, the available vaccines correspond to five types, which are administered at different vaccination sites every week:
- 18,418 doses of the quadrivalent inactivated vaccine – which can be given to infants starting at 6 months of age – is best targeted at the healthy general population between 6 and 23 months and between 60 and 64 years of age, as well as in high-risk groups (Vaxigrip tetra).
- Provide 42,000 doses of adjuvanted quadrivalent inactivated vaccine (Fluad tetra) to the non-institutionalized general population aged 65 years and older.
- 4,184 quadrivalent inactivated units with high antigenic load, suitable for people over 60 years of age in nursing homes and elderly people with a large number of dependents at home (Efluelda).
- 25 Quadrivalent inactivated vaccine for people allergic to antibiotics (Flucelvax tetra).
- 1,430 doses of an attenuated quadrivalent vaccine for intranasal administration, targeting children aged 24 to 59 months (Fluenz tetra, €445,454.10).